Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ORY.MC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.03
vs -0.03
Q2.23
+100%
0.02
vs 0.01
Q3.23
N/A
-0.02
vs -0.01
Q4.23
N/A
-0.03
vs -0.04
Q1.24
N/A
-0.02
vs -0.03
Q2.24
-91%
0
vs 0.02
Q3.24
N/A
-0.02
vs -0.02
Q4.24
N/A
-0.02
vs -0.03
Q1.25
N/A
-0.03
vs -0.02
Q2.25
N/A
-0.03
vs 0
Sales Growth
YoY
Current
Estimates
Q4.22
+48%
15.7M vs 10.6M
Q1.23
NA
NA vs NA
Q2.23
+4%
7.5M vs 7.2M
Q3.23
NA
NA vs NA
Q4.23
-10%
14.2M vs 15.7M
Q1.24
NA
NA vs NA
Q2.24
-45%
4.1M vs 7.5M
Q3.24
NA
NA vs NA
Q4.24
-48%
7.4M vs 14.2M
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q1.23
-2%
-0.02
vs NA
Q2.23
+1%
0.01
vs -0.02
Q3.23
-1%
-0.01
vs 0.01
Q4.23
-2%
-0.02
vs -0.01
Q1.24
-1%
-0.01
vs -0.02
Q2.24
+0%
0
vs -0.01
Q3.24
-1%
-0.01
vs 0
Q4.24
-1%
-0.01
vs -0.01
Institutionnal Ownership
Forecast
NaN%2026-Revenue
140%2026-EPS
-96%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
BME
Unprofitable
Unprofitable
0.01 ( 0.18%)
Relative Strenght
Volume Buzz
-18%
Earning Acce
No
Dist 52w H.
24%Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ORY.MC compares to sector?
ORY.MC
-51x